FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Porter

Research Profile

Chemicals & Drugs

Disorders

Procedures

Anatomy

Concepts & Ideas

Magnetic Resonance Imaging

Living Beings

Mouse

Co-author Network

Publications

TOP 3
John B Porter; Pranee Sutcharitchan; Ali T Taher; D Habr; S-H Lee; N Martin; Yesim Aydinok; L L Chan; M S Elalfy; Amal El-Beshlawy
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
Ratna Chatterjee; Bernard A Davis; Rekha Bajoria; Margaret Byers; Jean Pringle; Farrukh T Shah; Dev Sooranna; John B Porter
Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome.
Dudley J Pennell; John B Porter; Bernard Roubert; Gillian Smith; Vip Viprakasit; Yesim Aydinok; Maria Domenica Cappellini; Lee Lee Chan; Gabor Domokos; Mohsen S Elalfy; Amal El-Beshlawy; Dany Habr; Hishamshah Ibrahim; Antonis Kattamis; Chi-Kong Li; Ali Taher
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Porter (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: John B Porter; Pranee Sutcharitchan; Ali T Taher; D Habr; S-H Lee; N Martin; Yesim Aydinok; L L Chan; M S Elalfy; Amal El-Beshlawy
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
Annals of hematology 2013;92(2):211-9.
2012: Ratna Chatterjee; Bernard A Davis; Rekha Bajoria; Margaret Byers; Jean Pringle; Farrukh T Shah; Dev Sooranna; John B Porter
Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome.
British journal of haematology 2012;159(4):462-71.
2012: Dudley J Pennell; John B Porter; Bernard Roubert; Gillian Smith; Vip Viprakasit; Yesim Aydinok; Maria Domenica Cappellini; Lee Lee Chan; Gabor Domokos; Mohsen S Elalfy; Amal El-Beshlawy; Dany Habr; Hishamshah Ibrahim; Antonis Kattamis; Chi-Kong Li; Ali Taher
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.
Haematologica 2012;97(6):842-8.
2012: Yesim Aydinok; Patricia Evans; Chantal Y Manz; John B Porter
Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
Haematologica 2012;97(6):835-41.
2011: John B Porter; Michael Evangeli; Amal El-Beshlawy
Challenges of adherence and persistence with iron chelation therapy.
International journal of hematology 2011;94(5):453-60.
2011: John B Porter; Bernard Roubert; Ali Taher; Swee Lay Thein; Photis Beris; Gabor Domokos; Gian Luca Forni; Dany Habr; Kai-Hsin Lin
Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.
European journal of haematology 2011;87(4):338-48.
2011: Chontida Thephinlap; C Phisalaphong; N Lailerd; Nipon Chattipakorn; Pranee Winichagoon; J Vadolus; Suthat Fucharoen; John B Porter; Somdet Srichairatanakool
Reversal of cardiac iron loading and dysfunction in thalassemic mice by curcuminoids.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 2011;7(1):62-9.
2011: Dudley J Pennell; John B Porter; Maria Domenica Cappellini; Lee Lee Chan; Amal El-Beshlawy; Yesim Aydinok; Hishamshah Ibrahim; Chi-Kong Li; Vip Viprakasit; Mohsen Saleh Elalfy; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher
Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.
Haematologica 2011;96(1):48-54.
2010: John B Porter; Farrukh T Shah
Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
Hematology/oncology clinics of North America 2010;24(6):1109-30.
2010: John B Porter
Deferasirox--current knowledge and future challenges.
Annals of the New York Academy of Sciences 2010;1202():87-93.
2010: Patricia Evans; Reem Kayyali; Robert C Hider; John Eccleston; John B Porter
Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
Translational research : the journal of laboratory and clinical medicine 2010;156(2):55-67.
2010: Francisco Alpendurada; John-Paul Carpenter; Monica Deac; Paul Kirk; J Malcolm Walker; John B Porter; Winston Banya; Taigang He; Gill C Smith; Dudley J Pennell
Relation of myocardial T2* to right ventricular function in thalassaemia major.
European heart journal 2010;31(13):1648-54.
2010: Dudley J Pennell; John B Porter; Maria Domenica Cappellini; Amal El-Beshlawy; Lee Lee Chan; Yesim Aydinok; Mohsen Saleh Elalfy; Pranee Sutcharitchan; Chi kong Li; Hishamshah Ibrahim; Vip Viprakasit; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.
Blood 2010;115(12):2364-71.
2010: T Saewong; S Ounjaijean; Y Mundee; K Pattanapanyasat; Suthat Fucharoen; John B Porter; Somdet Srichairatanakool
Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 2010;6(2):57-64.
2010: John-Paul Carpenter; Francisco Alpendurada; Monica Deac; Alicia M Maceira; Maciej Garbowski; Paul Kirk; J Malcolm Walker; John B Porter; Farrukh T Shah; Winston Banya; Taigang He; Gillian C Smith; Dudley J Pennell
Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload.
Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 2010;12():24.
2009: John B Porter
Optimizing iron chelation strategies in beta-thalassaemia major.
Blood reviews 2009;23 Suppl 1():S3-7.
2009: P Kirk; M Roughton; John B Porter; J Malcolm Walker; Mark A Tanner; J Patel; D Wu; J Taylor; Mark A Westwood; L J Anderson; Dudley J Pennell
Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major.
Circulation 2009;120(20):1961-8.
2009: Chontida Thephinlap; C Phisalaphong; Suthat Fucharoen; John B Porter; Somdet Srichairatanakool
Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 2009;5(5):474-82.
2009: John B Porter
Deferasirox: an update.
Hemoglobin 2009;33 Suppl 1():S70-5.
2009: John B Porter
Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease.
Hemoglobin 2009;33 Suppl 1():S37-45.
2008: S Ounjaijean; Chontida Thephinlap; Udompun Khansuwan; C Phisalapong; Suthat Fucharoen; John B Porter; Somdet Srichairatanakool
Effect of green tea on iron status and oxidative stress in iron-loaded rats.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 2008;4(4):365-70.
2008: John B Porter; Ali T Taher; Maria Domenica Cappellini; Elliott P Vichinsky
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].
Hemoglobin 2008;32(6):601-7.
2008: Robert W Evans; R Rafique; Adel Zarea; Chiara Rapisarda; Richard Cammack; Patricia J Evans; John B Porter; Robert C Hider
Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera.
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 2008;13(1):57-74.
2007: John B Porter
Concepts and goals in the management of transfusional iron overload.
American journal of hematology 2007;82(12 Suppl):1136-9.
2007: Somdet Srichairatanakool; Chontida Thephinlap; C Phisalaphong; John B Porter; Suthat Fucharoen
Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 2007;3(5):469-74.
2007: Mark A Westwood; Farrukh T Shah; Lisa J Anderson; Julian W Strange; Mark A Tanner; Alicia M Maceira; Jo Howard; John B Porter; J Malcolm Walker; Beatrix Wonke; Dudley J Pennell
Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy.
Journal of magnetic resonance imaging : JMRI 2007;26(3):564-8.
2007: Mark A Westwood; Lisa J Anderson; Alicia M Maceira; Farrukh T Shah; Emma Prescott; John B Porter; Beatrix Wonke; J Malcolm Walker; Dudley J Pennell
Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron.
Journal of magnetic resonance imaging : JMRI 2007;25(6):1147-51.
2007: Chontida Thephinlap; S Ounjaijean; Udompun Khansuwan; Suthat Fucharoen; John B Porter; Somdet Srichairatanakool
Epigallocatechin-3-gallate and epicatechin-3-gallate from green tea decrease plasma non-transferrin bound iron and erythrocyte oxidative stress.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 2007;3(3):289-96.
2006: John B Porter
Deferasirox: An effective once-daily orally active iron chelator.
Drugs of today (Barcelona, Spain : 1998) 2006;42(10):623-37.
2006: Sharmini Desigan; Margaret A Hall-Craggs; C-P Ho; J Eliahoo; John B Porter
Degenerative disc disease as a cause of back pain in the thalassaemic population: a case-control study using MRI and plain radiographs.
Skeletal radiology 2006;35(2):95-102.
2005: Mark A Westwood; Beatrix Wonke; Alicia M Maceira; Emma Prescott; J Malcolm Walker; John B Porter; Dudley J Pennell
Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major.
Journal of magnetic resonance imaging : JMRI 2005;22(2):229-33.
2005: John B Porter
Monitoring and treatment of iron overload: state of the art and new approaches.
Seminars in hematology 2005;42(2 Suppl 1):S14-8.
2005: John B Porter; R Rafique; Somdet Srichairatanakool; Bernard A Davis; Farrukh T Shah; T Hair; P Evans
Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
Annals of the New York Academy of Sciences 2005;1054():155-68.
2004: Lisa J Anderson; Mark A Westwood; Sally Holden; Bernard Davis; Emma Prescott; Beatrix Wonke; John B Porter; J Malcolm Walker; Dudley J Pennell
Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance.
British journal of haematology 2004;127(3):348-55.
2004: Bernard A Davis; Caoimhe O'Sullivan; Peter H Jarritt; John B Porter
Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major.
Blood 2004;104(1):263-9.
2002: John B Porter; Bernard A Davis
Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia.
Best practice & research. Clinical haematology 2002;15(2):329-68.
2002: P L Pemberton; JF Down; John B Porter; Lesley Bromley
A retrospective observational study of pre-operative sickle cell screening.
Anaesthesia 2002;57(4):334-7.
2002: Zu D Liu; Reem Kayyali; Robert C Hider; John B Porter; Anthony E Theobald
Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators.
Journal of medicinal chemistry 2002;45(3):631-9.
2002: Bernard A Davis; John B Porter
Results of long term iron chelation treatment with deferoxamine.
Advances in experimental medicine and biology 2002;509():91-125.
2001: Reem Kayyali; John B Porter; Zu D Liu; Nathan A Davies; Jonathan H A Nugent; Chris E Cooper; Robert C Hider
Structure-function investigation of the interaction of 1- and 2-substituted 3-hydroxypyridin-4-ones with 5-lipoxygenase and ribonucleotide reductase.
The Journal of biological chemistry 2001;276(52):48814-22.
2001: John B Porter
Practical management of iron overload.
British journal of haematology 2001;115(2):239-52.
2001: Y Mundee; Nancy C Bigelow; Bruce H Davis; John B Porter
Flow cytometric method for simultaneous assay of foetal haemoglobin containing red cells, reticulocytes and foetal haemoglobin containing reticulocytes.
Clinical and laboratory haematology 2001;23(3):149-54.
2001: John B Porter
Deferoxamine pharmacokinetics.
Seminars in hematology 2001;38(1 Suppl 1):63-8.
2000: Y Mundee; Nancy C Bigelow; Bruce H Davis; John B Porter
Simplified flow cytometric method for fetal hemoglobin containing red blood cells.
Cytometry 2000;42(6):389-93.
2000: panos kottaridis; Karl S Peggs; A Lawrence; Stephanie Verfuerth; Ratna Chatterjee; P Telfer; John B Porter; Stephen Mackinnon; Anthony H Goldstone
One antigen mismatched related donor bone marrow transplant in a patient with acute lymphoblastic leukaemia and beta-thalassaemia major: potential cure of both marrow disorders.
Bone marrow transplantation 2000;25(6):677-8.
2000: SS Shoab; John B Porter; JOHN HENRY SCURR; PD Coleridge Smith
Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot study.
Journal of vascular surgery 2000;31(3):456-61.
2000: Bernard A Davis; John B Porter
Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia.
Blood 2000;95(4):1229-36.
1999: Sunitha N Wickramasinghe; S L Thein; Somdet Srichairatanakool; John B Porter
Determinants of iron status and bilirubin levels in congenital dyserythropoietic anaemia type I.
British journal of haematology 1999;107(3):522-5.
1999: B L Ellis; C B Sampson; R D Abeysinghe; John B Porter; Robert C Hider
6-Alkoxymethyl-3-hydroxy-4H-pyranones: potential ligands for cell-labelling with indium.
European journal of nuclear medicine 1999;26(11):1400-6.
1999: Edith Wiener; D Allen; R J Porter; Sunitha N Wickramasinghe; John B Porter; S Chinprasertsuk; Uamporn Siripanyaphinyo; Kovit Pattanapanyasat; Suthat Fucharoen; Wanchai Wanachiwanawin
Role of FcgammaRI (CD64) in erythrocyte elimination and its up-regulation in thalassaemia.
British journal of haematology 1999;106(4):923-30.
1998: Alison Curnow; BW McIlroy; M J Postle-Hacon; John B Porter; Alexander J MacRobert; Stephen G Bown
Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents.
British journal of cancer 1998;78(10):1278-82.
1998: John B Porter; A Faherty; L Stallibrass; L Brookman; I Hassan; C Howes
A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity.
Annals of the New York Academy of Sciences 1998;850():483-7.
1998: Ratna Chatterjee; Maurice Katz; Angela Oatridge; Graeme M Bydder; John B Porter
Selective loss of anterior pituitary volume with severe pituitary-gonadal insufficiency in poorly compliant male thalassemic patients with pubertal arrest.
Annals of the New York Academy of Sciences 1998;850():479-82.
1998: E Mollapour; John B Porter; R Kaczmarski; David C Linch; PJ Roberts
Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase A2 in sickle cell disease.
Blood 1998;91(9):3423-9.
1998: M Saharay; D A Shields; S N Georgiannos; John B Porter; JOHN HENRY SCURR; PD Coleridge Smith
Endothelial activation in patients with chronic venous disease.
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 1998;15(4):342-9.
1997: John B Porter
A risk-benefit assessment of iron-chelation therapy.
Drug safety : an international journal of medical toxicology and drug experience 1997;17(6):407-21.
1997: S J Bradley; I Gosriwitana; Somdet Srichairatanakool; R C Hider; John B Porter
Non-transferrin-bound iron induced by myeloablative chemotherapy.
British journal of haematology 1997;99(2):337-43.
1997: M Saharay; D A Shields; John B Porter; JOHN HENRY SCURR; PD Coleridge Smith
Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease.
Journal of vascular surgery 1997;26(2):265-73.
1997: SC Chang; Alexander J MacRobert; John B Porter; Stephen G Bown
The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study.
Journal of photochemistry and photobiology. B, Biology 1997;38(2-3):114-22.
1997: S Ratip; Mary Petrou; John M Old; Beatrix Wonke; John B Porter; Bernadette Modell
Relationship between the severity of beta-thalassaemia syndromes and the number of alleviating mutations.
European journal of haematology 1997;58(1):14-21.
1996: Chris E Cooper; G R Lynagh; K P Hoyes; Robert C Hider; Richard Cammack; John B Porter
The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase.
The Journal of biological chemistry 1996;271(34):20291-9.
1996: R D Abeysinghe; P J Roberts; Chris E Cooper; K H MacLean; Robert C Hider; John B Porter
The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators.
The Journal of biological chemistry 1996;271(14):7965-72.
1996: John B Porter
Evaluation of new iron chelators for clinical use.
Acta haematologica 1996;95(1):13-25.
1995: DC Rees; P Cervi; D Grimwade; A O'Driscoll; malcolm Hamilton; N E Parker; John B Porter
The metabolites of nitric oxide in sickle-cell disease.
British journal of haematology 1995;91(4):834-7.
1995: A O'Driscoll; Ian J Mackie; John B Porter; S J Machin
Low plasma heparin cofactor II levels in thalassaemia syndromes are corrected by chronic blood transfusion.
British journal of haematology 1995;90(1):65-70.
1994: R D Abeysinghe; B L Ellis; John B Porter
Platelet labelling with indium-hydroxypyridinone and indium-hydroxypyranone complexes.
European journal of nuclear medicine 1994;21(10):1141-7.
1994: R O Epemolu; R Ackerman; John B Porter; Robert C Hider; Lyaquat A Damani; S Singh
HPLC determination of 1,2-diethyl-3-hydroxypyridin-4-one (CP94), its iron complex [Fe(III) (CP94)3] and glucuronide conjugate [CP94-GLUC] in serum and urine of thalassaemic patients.
Journal of pharmaceutical and biomedical analysis 1994;12(7):923-30.
1994: John B Porter; S Singh; K P Hoyes; O Epemolu; R D Abeysinghe; Robert C Hider
Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds.
Advances in experimental medicine and biology 1994;356():361-70.
1994: Robert C Hider; O Epemolu; S Singh; John B Porter
Iron chelator design.
Advances in experimental medicine and biology 1994;356():343-9.
1993: K P Hoyes; John B Porter
Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.
British journal of haematology 1993;85(2):393-400.
1993: John B Porter; R D Abeysinghe; K P Hoyes; C Barra; E R Huehns; P N Brooks; M P Blackwell; M Araneta; G Brittenham; S Singh
Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating site.
British journal of haematology 1993;85(1):159-68.
1993: R Chatterjee; M Katz; T F Cox; John B Porter
Prospective study of the hypothalamic-pituitary axis in thalassaemic patients who developed secondary amenorrhoea.
Clinical endocrinology 1993;39(3):287-96.
1993: P S Dobbin; Robert C Hider; A D Hall; P D Taylor; P Sarpong; John B Porter; G Xiao; Dick van der Helm
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
Journal of medicinal chemistry 1993;36(17):2448-58.
1993: P Lee; N Mohammed; L Marshall; R D Abeysinghe; Robert C Hider; John B Porter; S Singh
Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients.
Drug metabolism and disposition: the biological fate of chemicals 1993;21(4):640-4.
1993: John B Porter; L Young; Ian J Mackie; L Marshall; S J Machin
Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor II.
British journal of haematology 1993;83(3):459-65.
1993: K P Hoyes; Hilary Jones; R D Abeysinghe; Robert C Hider; John B Porter
In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.
Experimental hematology 1993;21(1):86-92.
1992: K P Hoyes; Robert C Hider; John B Porter
Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines.
Cancer research 1992;52(17):4591-9.
1992: S Singh; N Mohammed; R Ackerman; John B Porter; Robert C Hider
Quantification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and simultaneous ultraviolet-visible/radioactive detection.
Analytical biochemistry 1992;203(1):116-20.
1991: John B Porter; K P Hoyes; R D Abeysinghe; P N Brooks; E R Huehns; Robert C Hider
Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice.
Blood 1991;78(10):2727-34.
1990: John B Porter; J Morgan; K P Hoyes; L C Burke; E R Huehns; Robert C Hider
Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice.
Blood 1990;76(11):2389-96.
1990: S Singh; Robert C Hider; John B Porter
Separation and identification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and fast atom bombardment mass spectrometry: choice of complexing agent and application to biological fluids.
Analytical biochemistry 1990;187(2):212-9.
1990: S Singh; Robert C Hider; John B Porter
A direct method for quantification of non-transferrin-bound iron.
Analytical biochemistry 1990;186(2):320-3.
1990: Robert C Hider; L Ejim; P D Taylor; R Gale; E Huehns; John B Porter
Facilitated uptake of zinc into human erythrocytes. Relevance to the treatment of sickle-cell anaemia.
Biochemical pharmacology 1990;39(6):1005-12.
1990: Brian R Davidson; Paul B Boulos; John B Porter
Inhibition of the hepatocyte uptake of radiolabelled monoclonal antibodies by chelating agents.
European journal of nuclear medicine 1990;17(6-8):294-8.
1990: Stephen Devereux; John B Porter; K P Hoyes; R D Abeysinghe; R Saib; David C Linch
Secretion of neutrophil secondary granules occurs during granulocyte-macrophage colony stimulating factor induced margination.
British journal of haematology 1990;74(1):17-23.
1989: John B Porter; M S Jaswon; E R Huehns; C A East; J W Hazell
Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.
British journal of haematology 1989;73(3):403-9.
1989: John B Porter; K P Hoyes; R Abeysinghe; E R Huehns; Robert C Hider
Animal toxicology of iron chelator L1.
Lancet 1989;2(8655):156.
1988: John B Porter; M Gyparaki; L C Burke; E R Huehns; P Sarpong; V Saez; Robert C Hider
Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant.
Blood 1988;72(5):1497-503.
1987: M Gyparaki; John B Porter; S Hirani; M Streater; Robert C Hider; E R Huehns
In vivo evaluation of hydroxypyridone iron chelators in a mouse model.
Acta haematologica 1987;78(2-3):217-21.
1987: John B Porter; E R Huehns
Transfusion and exchange transfusion in sickle cell anaemias, with particular reference to iron metabolism.
Acta haematologica 1987;78(2-3):198-205.